STOCKS TELEGRAPH

Tag: CODX

  • 10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    Healthcare is a dynamic and opportunity-rich industry. The demand for innovations that brings improvement in health outcomes, affordability, quality, and access will continue to be high. The changes we witnessed in the healthcare industry today have set a new tone for the change in the coming few years. 2020 is the year of change for the health care industry.

    The first thing which played an important role in the healthcare industry is Technology. Technology is continuously changing and brings new improvement in the healthcare industry. Patients today want easier and affordable access to care and better demand services. In this changing environment, diagnostics is emerging as a key driver in helping to address these needs.

    Here are the top 10 leading companies in Diagnostics Research Industry that need your attention:

    OPKO Health Inc. (NASDAQ: OPK)

    OPKO Health Inc. (NASDAQ: OPK) shares were trading down -0.92% at $3.22 at the time of writing on Tuesday. OPKO Health Inc. (NASDAQ: OPK) share price went from a low point around $1.12 to briefly over $6.47 in the past 52 weeks, though shares have since pulled back to $3.22. OPK market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 2.

    OPKO Health Inc. has earlier started a Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19.  If we look at the recent analyst rating OPK, Piper Jaffray initiated coverage on OPK shares with an Overweight rating.

    Pacific Biosciences of California Inc. (NASDAQ: PACB)

    Pacific Biosciences of California Inc. (NASDAQ: PACB) last closed at $8.78, in a 52-week range of $2.20 to $8.38. Analysts have a consensus price target of $6.50. Pacific Biosciences of California Inc. (PACB) has announced it has appointed Susan G. Kim as Chief Financial Officer. The decision is effective as of September 28, 2020. Susan has joined the company at a time when there are various growth opportunities for the company.

    Bionano Genomics Inc. (NASDAQ: BNGO)

    Bionano Genomics Inc. (NASDAQ: BNGO) stock soar by 0.79% to $0.64. The most recent rating by Oppenheimer, on April 08, 2020, is at an Outperform. Bionano Genomics Inc. (BNGO) will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. the summit is scheduled to take place virtually on September 21-23, 2020. This company market capitalization has remained high, hitting $90.45 million at the time of writing.

    Illumina Inc. (NASDAQ: ILMN)

    Illumina Inc. (NASDAQ: ILMN) shares headed falling, lower as much as -0.60%. The most recent rating by UBS, on September 22, 2020, is at a Neutral. Illumina Inc. (ILMN) has officially revealed an agreement to buy cancer-testing company Grail for about $8 billion in cash and stock. This company market capitalization has remained high, hitting $39.54 billion at the time of writing.

    Precipio Inc. (NASDAQ: PRPO)

    Precipio Inc. (NASDAQ: PRPO) shares headed rising, higher as much as 2.63%. Precipio Inc. has revealed that it has introduced its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This company market capitalization has remained high, hitting 37.42 million at the time of writing.

    Fulgent Genetics Inc. (NASDAQ: FLGT)

    Fulgent Genetics Inc. (NASDAQ: FLGT) stock soar by 7.08% to $40.25. The most recent rating by Oppenheimer, on August 20, 2020, is at an Outperform. Fulgent Genetics Inc. (FLGT) will replace Garrett Motion Inc. (GTX) in the S&P SmallCap 600 effective before the opening of trading on Friday, September 25. This company’s market capitalization has remained high, hitting $821.10 million at the time of writing.

    Fluidigm Corporation (NASDAQ: FLDM)

    Fluidigm Corporation (NASDAQ: FLDM) fall -1.29% after losing more than -$0.11 on Tuesday. In the past 52-weeks of trading, this company’s stock fluctuated between the low range of $1.17 and a high range of $12.45. It has moved up 595.73% from its 52-weeks low and moved down -34.62% from its 52-weeks high. Looking at its liquidity it has a current ratio of 2.00. This company’s market capitalization has remained high, hitting $523.91 million at the time of writing.

    Invitae Corporation (NYSE: NVTA)

    Invitae Corporation (NYSE: NVTA) last closed at $43.10, in a 52-week range of $7.41 to $40.96. Analysts have a consensus price target of $36.25. Invitae Corporation (NVTA) has moved up 475.19% from its 52-weeks low and moved down -2.16% from its 52-weeks high. Looking at its liquidity it has a current ratio of 3.70. This company’s market capitalization has remained high, hitting $5.56 billion at the time of writing.

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM)

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) fall -8.01% after losing more than -$0.03 on Tuesday. HTG Molecular Diagnostics Inc. (HTGM) share price went from a low point around $0.27 to briefly over $0.99 in the past 52 weeks, though shares have since pulled back to $0.32. HTG Molecular Diagnostics Inc. market cap has remained high, hitting $22.70 million at the time of writing

    Co-Diagnostics Inc. (NASDAQ: CODX)

    Co-Diagnostics Inc. (NASDAQ: CODX) last closed at $14.93, in a 52-week range of $0.85 to $30.99. Co-Diagnostics Inc. (CODX) has moved up 1567.08% from its 52-weeks low and moved down -54.47% from its 52-weeks high. Looking at its liquidity it has a current ratio of 11.60. This company’s market capitalization has remained high, hitting $404.90 million at the time of writing.

  • Why Co-Diagnostics Inc (CODX) Stock Bullish Reversal Could Mark the Start of a New Uptrend

    Why Co-Diagnostics Inc (CODX) Stock Bullish Reversal Could Mark the Start of a New Uptrend

    Its good day for Co-Diagnostics Inc [NASDAQ:CODX] investors. After several months in the red, the stock has rocketed today and is currently up by 31%. The rally follows the company’s announcement that it had made an agreement with Arches Research Inc for the expansion of Arche’s COVID-19 testing services. This will be implemented using Co-Diagnostics’ test kit called Logix Smart.

    The deal is a continuation of a relationship that started earlier in the year when Arches Research began using the Co-Diagnostics kits for testing. The signing of the deal comes just days after a 3rd party study on the kits concluded that their performance was good and that they could be used in smoothening out the process of reopening workplaces, schools, and other amenities.

    Commenting on the agreement, Co-Diagnostics CEO Dwight Egan stated that they were happy with the expanded relationship with one of the company’s most valued lab clients. He added that they were optimistic that the expanded relationship would open new opportunities to sell not just test kits, but other diagnostic products that the company was working on. Some of the products that it has under development include the upcoming Logix Smart Flu A/ Flu B and COVID-19 kits.

    What next?

    With this deal in place, this stock’s current bullish reversal could mark the start of a new uptrend. That’s because, with the expanded deal, the company’s revenues will grow in coming quarters. This will mean a higher intrinsic value for the company and by extension its price.  On top of that, investors anticipating stronger earnings in the near-term are likely to keep bidding up the stock price in the near-term. This is already happening as can be seen in the sustained increase in price since the company announced the expanded deal.

    There is also the fact that with the 3rd party validation of the company’s test kits, other companies and even governments are likely to start making their orders for its COVID-19 test kits. That’s because, while the world is awaiting a vaccine, testing remains the most effective way to fully get the economy working optimally again in the near-term. It is through testing that establishments that deal with lots of people can reopen safely, by isolating those who have COVID-19 from the rest of society. Testing also presents an opportunity for governments to understand the patterns of the disease and model it for policy decision-making on COVID-19.

    About Co-Diagnostics Inc

    Co-Diagnostics Inc is a molecular diagnostics corporation. It is based in Salt Lake, Utah.